It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The pharmacokinetic variability of lamotrigine (LTG) plays a significant role in its dosing requirements. Our goal here was to use noninvasive clinical parameters to predict the dose-adjusted concentrations (C/D ratio) of LTG based on machine learning (ML) algorithms. A total of 1141 therapeutic drug-monitoring measurements were used, 80% of which were randomly selected as the "derivation cohort" to develop the prediction algorithm, and the remaining 20% constituted the "validation cohort" to test the finally selected model. Fifteen ML models were optimized and evaluated by tenfold cross-validation on the "derivation cohort,” and were filtered by the mean absolute error (MAE). On the whole, the nonlinear models outperformed the linear models. The extra-trees’ regression algorithm delivered good performance, and was chosen to establish the predictive model. The important features were then analyzed and parameters of the model adjusted to develop the best prediction model, which accurately described the C/D ratio of LTG, especially in the intermediate-to-high range (≥ 22.1 μg mL−1 g−1 day), as illustrated by a minimal bias (mean relative error (%) = + 3%), good precision (MAE = 8.7 μg mL−1 g−1 day), and a high percentage of predictions within ± 20% of the empirical values (60.47%). This is the first study, to the best of our knowledge, to use ML algorithms to predict the C/D ratio of LTG. The results here can help clinicians adjust doses of LTG administered to patients to minimize adverse reactions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Department of Pharmacy, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072); Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China (GRID:grid.410737.6)
2 Guangzhou Bureau of Civil Affairs Psychiatric Hospital, Department of Pharmacy, Guangzhou, China (GRID:grid.410737.6)
3 Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, China (GRID:grid.410737.6); The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Institute of Neuropsychiatry, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
4 The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Department of Pharmacy, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)